{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"}],"units":"Participants"}],"description":"Here is the number of participants with adverse events. For a detailed list of adverse events, see the adverse event module.","groups":[{"description":"20 mg/kg intravenous over 60 minutes or not to exceed 25 mg/minute once every 3 weeks (+ or -1 day cycle 3 and beyond)","id":"OG000","title":"IMC-A12 Monotherapy in Patients"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"Date treatment consent signed to date off study, approximately 36 months","title":"Safety of IMC-A12 in Patients With Mesothelioma","type":"SECONDARY","unitOfMeasure":"Participants"}